Fig. 1
From: Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma
Inhibitory effects of MP1 on MB cell growth and MYC protein expression. A MTT (cell growth) assay showing dose-dependent growth effects of MP1 with the low-µM doses as indicated, in MB cell lines (with corresponding IC50) at 48 h. Percentage of viable cells is relative to DMSO- (solvent control)-treated cells. Plotted values and error bars represent mean ± SEM. B Western blot results show dose-dependent effect of MP1 on MYC protein expression in MYC-amplified MB cell lines at 24 h. C MTT assay showing the sensitization of MYC overexpressed ONS-76 (ONS-76 MYC-OE) cells to MP1 (48 h) treatment compared to the control ONs-76 RFP cells. Plotted values and error bars represent mean ± SEM. Control ONS-76 vs ONS-76 MYC-OE; p < 0.01 (Student-t-test). D MYC protein expression in MYC overexpressed ONS-76 and ONS-76 control cells treated with 0.25 µM MP1 for 24 h. E Quantification of the number of spheres following dose-dependent treatment of MP1 in two PDX-derived MB cell lines (MED-411FH, MED-114FH) at 72 h. Values, mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001 (Student-t-test). Below are western blot results showing corresponding changes in MYC protein expression after MP1 treatment. GAPDH was used as the loading control in all western blot experiments presented in this figure